Authors: DIVGI CR BANDER NH SCOTT AM ODONOGHUE JA SGOUROS G WELT S FINN RD MORRISSEY F CAPITELLI P WILLIAMS JM DELAND D NAKHRE A OOSTERWIJK E GULEC S GRAHAM MC LARSON SM OLD LJ

Citation: Cr. Divgi et al., PHASE I II RADIOIMMUNOTHERAPY TRIAL WITH IODINE-131-LABELED MONOCLONAL-ANTIBODY G250 IN METASTATIC RENAL-CELL CARCINOMA/, Clinical cancer research, 4(11), 1998, pp. 2729-2739

Authors: LOH A SGOUROS G ODONOGHUE JA DELAND D PURI D CAPITELLI P HUMM JL LARSON SM OLD LJ DIVGI CR

Citation: A. Loh et al., PHARMACOKINETIC MODEL OF IODINE-131-G250 ANTIBODY IN RENAL-CELL CARCINOMA PATIENTS, The Journal of nuclear medicine, 39(3), 1998, pp. 484-489

Authors: SGOUROS G LOH AC ODONOGHUE JA DELAND D PURI D CAPITELLI P HUMM JL LARSON SM OLD LJ DIVGI CR

Citation: G. Sgouros et al., G250 ANTIBODY PHARMACOKINETIC PARAMETERS FOR A MODEL OF TUMOR RESPONSE IN RADIOIMMUNOTHERAPY, The Journal of nuclear medicine, 38(5), 1997, pp. 975-975

Authors: SGOUROS G DELAND D LOH AC DIVGI CR LARSON SM

Citation: G. Sgouros et al., MARROW AND WHOLE-BODY ABSORBED DOSE VS MARROW TOXICITY FOLLOWING I-131 G250 ANTIBODY THERAPY IN PATIENTS WITH RENAL-CELL CARCIONOMA, The Journal of nuclear medicine, 38(5), 1997, pp. 1064-1064